Valion Bio, Inc. (VBIO) · Oct 29, 2026 · Other events
Above the bar — No treatment-related toxicity at 0.72 mg/kg over 14 days
Valion Bio’s safety study for Entolimod found no treatment-related toxicity, clearing the way for a government-funded therapeutic study focused on survival and GI recovery.
Valion is a recently refocused biopharma built around Entolimod and its TLR5 platform, after moving away from its former bioelectronic focus; the company is now trying to turn government-supported radiation-countermeasure research into its lead development path.
The safety hurdle was cleared cleanly. In a 20-mouse study, a single 0.72 mg/kg dose produced stable weight, normal blood counts, and normal metabolic and organ-function measures over 14 days. 〔0〕 〔1〕
This is a genuine step forward, but not an efficacy readout. The result removes a tolerability obstacle to the next AFRRI experiment, which will test the outcomes that matter commercially and regulatorily—survival and gastrointestinal recovery after radiation. 〔2〕
The direction was partly expected, so the surprise is limited to execution. Valion had already said in August 2026 that AFRRI planned to run the safety study first and then move into a therapeutic study if tolerability was confirmed; this filing confirms the condition was met, but does not provide a start date, efficacy data, or a new regulatory milestone.
The fully funded study helps the program more than the balance sheet. Government funding should reduce the immediate burden of this specific experiment, but it does not resolve Valion’s broader financing pressure: as of June 30, 2026, the company reported $2.1 million of cash and substantial doubt about funding operations for the following twelve months.
Bottom line: This is a modestly positive development because Entolimod cleared the required safety check and can move to the decisive survival study. It advances the program, but the central value question—whether the drug works after radiation exposure—remains unanswered.
AFRRI therapeutic study on survival and GI recovery
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!